News

PipelineReview.com7m
EphA2 targeting PDC drug SC-102 received Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA)
I On May 30, 2025, Conjustar Biologics announced that it's EphA2 targeting PDC drug SC-102 has received Investigational New Drug (IND) approval ...
PipelineReview.com14m
Biocytogen and Nanjing Chia Tai Tianqing Announce IND Approval in China for Co-Developed Anti-IGF-1R Antibody NTB003 (BCG009)
BEIJING, China & NANJING, China, China I June 04, 2025 I Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) and Nanjing Chia Tai ...
PipelineReview.com15m
Acerand Therapeutics Initiates First-in-Human Phase I Clinical Trial of ACE-232, a Novel CYP11A1 Inhibitor for Advanced Prostate Cancer
SHANGHAI, China & INDIANAPOLIS, IN, USA I June 04, 2025 I Acerand Therapeutics, a clinical-stage biotech company focusing on the discovery and development ...
PipelineReview.com33m
Biodexa Announces Recruitment of First Patient in Phase 2 Study of Tolimidone in Type 1 Diabetes
I Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of ...
PipelineReview.com36m
AstriVax Therapeutics Initiates Clinical Development of AVX70371, a Hepatitis B immunotherapy using Launch-iT technology
LEUVEN, Belgium I June 5, 2025 I AstriVax Therapeutics NV, a clinical stage immunotherapy company developing novel treatments for chronic infections based on ...